Shorla Oncology Expands into the U.S.

CEO Sharon Cunningham will relocate to Boston to lead the transatlantic expansion and commercial strategy of the company. Shorla prepares to launch its first U.S. product, SH-111, a treatment for children with T-cell Leukemia. “This is an important step in our commercialization planning. As a company breaking new ground in the treatment of cancers, with our first product targeted for launch later in the year, we believe now is the right time to establish our U.S. operations.”

Read more at: